• Amarin reported new post hoc findings from the REDUCE-IT trial, presented at the European Atherosclerosis Society Congress 2026.
• The analysis suggests a risk-weighted apoB measure may better flag residual cardiovascular risk in statin-treated patients with high triglycerides than standard lipid markers.
• Results imply conventional apoB readings may understate lipid-related risk in this population, potentially shifting how clinicians identify candidates for additional therapy.
• The update reinforces the clinical positioning of icosapent ethyl in guideline-driven care for high-risk patients with persistent triglyceride-related risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270800PRIMZONEFULLFEED9726898) on May 27, 2026, and is solely responsible for the information contained therein.